If you are a member of the general public and not a healthcare professional, NOVELTY study investigator or AstraZeneca Medical employee, please CLICK HERE to see information tailored to you.
We are pleased to announce that a new article entitled ‘Treatable traits in the NOVELTY study’ has been published in Respirology.
Asthma and COPD are complex conditions that require personalised management, for which the identification and use of treatable traits has been proposed. This article reports the prevalence of 30 expert-selected treatable traits and the relationships of their presence/absence with physician-assigned diagnosis of asthma and/or COPD and physician-assessed severity.
Treatable trait prevalence varied greatly; there were no large global geographical variations, but the prevalence differed between primary and specialised care. Asthma+COPD had the highest mean number of treatable traits per patient and asthma the lowest. A few treatable traits were tightly linked with the diagnostic labels of asthma and COPD, while many others occurred independently of these labels.
This work provides the largest and most granular characterisation of treatable traits in patients with asthma and/or COPD in a real-world setting to date. Treatments that target traits, regardless of diagnosis and severity, may lead to precision medicine for asthma and/or COPD, and may result in better patient outcomes.
The full article is available here.
Read a summary of this article, and other NOVELTY publications and presentations here.
You are now leaving: http://aznoveltyproject.com/
By following this link you will be leaving the NOVELTY study website.
Please note that AstraZeneca does not take responsibility for the content displayed on other websites.